Market News & Trends
Genelux Corporation Initiates Pivotal Phase 3 Trial Evaluating Olvi-Vec for the Treatment of Platinum-Resistant/Refractory Ovarian Cancer
Genelux Corporation recently announced it has initiated OnPrime, a multi-center, randomized, open-label Phase 3 registrational trial evaluating the efficacy and safety of Olvi-Vec in combination…
Immunic Announces Positive Results from Single & Multiple Ascending Dose Parts of its Phase 1 Clinical Trial
Immunic, Inc. recently announced positive unblinded safety, tolerability and pharmacokinetic (PK) results from Part A (single ascending doses, SAD) and Part B (multiple ascending doses, MAD)…
Decibel Therapeutics Announces Submission of IND Application for Lead Gene Therapy Candidate
Decibel Therapeutics recently announced the submission of an Investigational New Drug (IND) application to the US FDA for a Phase 1/2 clinical trial in pediatric…
Evoke Pharma Receives Notice of Allowance From USPTO for a Patent Related to GIMOTI
Evoke Pharma, Inc. recently announced the USPTO issued a Notice of Allowance for US Application No. 16/469,092 for GIMOTI. When granted, the patent will cover…
GENFIT to Acquire Clinical-Stage Biopharmaceutical Company, Expanding its Portfolio in Liver Diseases
GENFIT recently announced it has entered into an exclusivity agreement with a view to acquire all the share capital and voting rights of Versantis, a private…
RIGImmune Announces Acquisition of Antiviral Company Subintro
RIGImmune Inc. recently announced the acquisition of Subintro, a biotechnology company specializing in the development and delivery of antiviral therapeutics for respiratory diseases caused by…
Thermo Fisher Scientific’s PPD Clinical Research Business Selected to Support National Cancer Institute’s Cancer Trials Support Unit
The PPD clinical research business of Thermo Fisher Scientific Inc. has been awarded a 10-year Indefinite-Delivery, Indefinite-Quantity (IDIQ) contract by the National Cancer Institute (NCI),…
Lonza Expands HPAPI Multipurpose Suite for Payload-Linker Manufacturing in Visp (CH)
Lonza recently announced the completion of the expansion of its Highly Potent API (HPAPI) multipurpose suite in Visp (CH). The expansion adds development and manufacturing…
Oxford Biomedica Solutions Signs Agreement With New Partner to Deliver the Full Solution for Its AAV Programs
Oxford Biomedica Solutions LLC recently announced it has signed an agreement with an undisclosed US-based private biotechnology company. The agreement will provide The Full Solution…
Vaxxinity Announces First Subjects Dosed in Phase 1 Clinical Trial of UB-313 for Preventive Treatment of Migraine
Vaxxinity, Inc. recently announced the first subjects have been dosed in a Phase 1 clinical trial of UB-313, a vaccine targeting calcitonin gene-related peptide (CGRP),…
EXCLUSIVE ONLINE CONTENT
Molex Expands European Manufacturing Footprint & Capabilities With State-of-the-Art Campus in Poland
Molex recently announced a major expansion of its global manufacturing footprint with the opening of a new campus in Katowice, Poland. The facility’s initial 23,000-square-meter manufacturing space will….
Kala Pharmaceuticals Completes Sale of EYSUVIS & INVELTYS to Alcon Inc
Kala Pharmaceuticals, Inc. recently announced it has completed the sale of its commercial portfolio and related intellectual property assets to Alcon Inc., a transaction that was….
Insightful Science Acquires Protein Metrics to Expand its R&D Solution to Include Proteomics
Insightful Science recently announced it has completed the transaction to acquire Protein Metrics, Inc. to expand the company’s R&D value chain to widen the biopharmaceutical protein analysis arena….
Acer Therapeutics & Relief Therapeutics Announce NDA Submission for ACER-001 for Treatment of Urea Cycle Disorders
Acer Therapeutics Inc. Relief Therapeutics recently announced the submission of a New Drug Application (NDA) to the US FDA for ACER-001 (sodium phenylbutyrate) for the treatment of Urea Cycle Disorders (UCDs)….